GAMMA Investing LLC Has $237,000 Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS)

GAMMA Investing LLC grew its position in Keros Therapeutics, Inc. (NASDAQ:KROS) by 7,690.3% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 2,415 shares of the company’s stock after buying an additional 2,384 shares during the period. GAMMA Investing LLC’s holdings in Keros Therapeutics were worth $237,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. AlphaQuest LLC increased its stake in shares of Keros Therapeutics by 469.0% in the 4th quarter. AlphaQuest LLC now owns 3,596 shares of the company’s stock valued at $57,000 after buying an additional 2,964 shares during the period. Virtus ETF Advisers LLC boosted its position in shares of Keros Therapeutics by 107.5% in the 4th quarter. Virtus ETF Advisers LLC now owns 3,857 shares of the company’s stock worth $61,000 after purchasing an additional 1,998 shares during the last quarter. KLP Kapitalforvaltning AS bought a new position in shares of Keros Therapeutics in the 4th quarter worth $90,000. CANADA LIFE ASSURANCE Co boosted its position in shares of Keros Therapeutics by 207.8% in the 4th quarter. CANADA LIFE ASSURANCE Co now owns 7,371 shares of the company’s stock worth $116,000 after purchasing an additional 4,976 shares during the last quarter. Finally, ProShare Advisors LLC boosted its position in shares of Keros Therapeutics by 35.5% in the 4th quarter. ProShare Advisors LLC now owns 10,549 shares of the company’s stock worth $167,000 after purchasing an additional 2,764 shares during the last quarter. 71.56% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. Wedbush restated a “neutral” rating and issued a $15.00 price target on shares of Keros Therapeutics in a research report on Friday, May 30th. Scotiabank reduced their price target on Keros Therapeutics from $41.00 to $26.00 and set a “sector outperform” rating on the stock in a research report on Monday, May 12th. Bank of America lowered Keros Therapeutics from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $32.00 to $18.00 in a research report on Tuesday, June 10th. Wells Fargo & Company reduced their price target on Keros Therapeutics from $28.00 to $26.00 and set an “overweight” rating on the stock in a research report on Thursday, February 27th. Finally, HC Wainwright reduced their price target on Keros Therapeutics from $40.00 to $25.00 and set a “buy” rating on the stock in a research report on Thursday, May 8th. Seven equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $30.56.

Insider Activity

In other news, major shareholder Adar1 Capital Management, Llc purchased 934,258 shares of the business’s stock in a transaction dated Wednesday, April 9th. The shares were bought at an average cost of $10.13 per share, for a total transaction of $9,464,033.54. Following the completion of the acquisition, the insider now directly owns 4,392,737 shares in the company, valued at approximately $44,498,425.81. This trade represents a 27.01% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 20.60% of the company’s stock.

Keros Therapeutics Trading Down 0.4%

NASDAQ:KROS opened at $13.49 on Friday. Keros Therapeutics, Inc. has a 1 year low of $9.12 and a 1 year high of $72.37. The stock has a market cap of $547.96 million, a price-to-earnings ratio of -74.94 and a beta of 1.31. The stock has a 50-day moving average price of $14.07 and a two-hundred day moving average price of $14.89.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings results on Tuesday, May 6th. The company reported $3.62 EPS for the quarter, beating analysts’ consensus estimates of ($0.01) by $3.63. The company had revenue of $211.25 million for the quarter, compared to analyst estimates of $84.62 million. Keros Therapeutics had a return on equity of 0.75% and a net margin of 1.96%. During the same period in the previous year, the company posted ($1.21) earnings per share. Sell-side analysts forecast that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.